BeOne Medicines jumps as Wolfe Research initiates with Outperform, $340 target
BeOne Medicines (ONC) shares rose after Wolfe Research initiated coverage with an Outperform rating and a $340 price target. The call highlighted confidence in BRUKINSA’s durability in first-line CLL and potential expansion into fixed-duration, all-oral combinations.
1. What’s moving the stock today
BeOne Medicines’ American Depositary Shares (ONC) traded higher as investors reacted to a fresh bullish analyst initiation. Wolfe Research started coverage with an Outperform rating and set a $340 price target, putting a new spotlight on the company’s core growth engine and pipeline optionality. (investing.com)
2. The key bull case: BRUKINSA durability and new regimen potential
The initiation framed BRUKINSA as the central value driver, emphasizing expectations that it can remain highly competitive in first-line chronic lymphocytic leukemia (CLL) as a continuous BTK inhibitor while also expanding into fixed-duration therapy in an all-oral combination approach. This narrative supports the view that BeOne can widen its addressable market beyond today’s standard usage patterns, helping sustain growth even as the BTK category evolves. (investing.com)
3. What investors are watching next
With the stock already priced for strong execution, the next leg of performance typically hinges on whether product momentum and pipeline milestones continue to validate the growth outlook. BeOne’s latest full-year update included 2026 total revenue guidance of $6.2 billion to $6.4 billion, which remains a reference point for expectations as the year progresses. (flcube.com)
4. Context: mixed sell-side signals in recent weeks
Today’s move comes amid a noisy analyst backdrop. Earlier in March, Jefferies shifted to a more cautious stance, downgrading ONC to Hold, underscoring that opinions differ on valuation and near-term risk/reward even as the company posts strong operating trends. (fintel.io)